Cell line development represents a crucial step in the development process of a therapeutic
glycoprotein. Chinese hamster ovary (CHO) cells are the most frequently employed …

Recent advances in omics technologies and the broad availability of big datasets have
revolutionized our understanding of Chinese hamster ovary cells in their role as the most …

Historically, therapeutic protein production in Chinese hamster ovary (CHO) cells has been
accomplished by random integration (RI) of expression plasmids into the host cell genome …

Many branches of biology depend on stable and predictable recombinant gene expression,
which has been achieved in recent years through targeted integration of the recombinant …

The use of targeted integration for industrial CHO cell line development currently requires
significant upfront effort to identify genomic loci capable of supporting multigram per liter …

Chinese hamster ovary cells, commonly used in the production of therapeutic proteins, are
aneuploid. Their chromosomes bear structural abnormality and undergo changes in …

Therapeutic antibodies are decorated with complex-type N-glycans that significantly affect
their biodistribution and bioactivity. The N-glycan structures on antibodies are incompletely …

With the emergence of new CRISPR/dCas9 tools that enable site specific modulation of
DNA methylation and histone modifications, more detailed investigations of the contribution …

There are an ever‐increasing number of biopharmaceutical candidates in clinical trials
fueling an urgent need to streamline the cell line development process. A critical part of the …

Abstract Chinese Hamster Ovary (CHO) cell lines are considered to be the preferred
platform for the production of biotherapeutics, but issues related to expression instability …